Mount Capital’s Moderna MRNA Stock Holding History
Bought
Maintained
Sold
Other funds holding MRNA
TP
Mount Capital's MRNA Position: Q3 2026 in Review
Mount Capital reduced its Moderna (MRNA) stake by 50% in Q3 2026, selling an estimated $24.5M and leaving 230,416 shares worth $44.4M. The position accounts for 13.94% of the portfolio, ranked #2.
Mount Capital first reported a position in MRNA in Q1 2026 and has held it in 3 quarters since. 1,053 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.
- Mount Capital held 230,416 shares of Moderna worth $44.4M as of Q3 2026.
- Mount Capital sold 227,484 Moderna shares in Q3 2026, an estimated $24.5M.
- Moderna made up 13.94% of Mount Capital's portfolio in Q3 2026, its #2 holding.
- Mount Capital first reported a position in Moderna in Q1 2026 and has held it in 3 quarters since.
- 1,053 funds tracked by Wall St. Rank held Moderna as of Q3 2026.
Based on Mount Capital's 13F filing for Q3 2026, filed 13 Nov 2026.